Corbus Pharmaceuticals Holdings Inc
Research Corbus Pharmaceuticals Holdings Inc (CRBP) on Bullrun: market cap USD 211.17M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRBP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 211.17M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 35.04M
- Free cash flow-USD 29.63M
Valuation Snapshot
latest market cap is USD 211.17M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 78.54M | -USD 64.50M | n/a | -5.9 | USD 28.49M | USD 1.63M | USD 147.50M |
| FY2024 | USD 0 | -USD 40.21M | -USD 41.79M | n/a | -3.68 | USD 17.20M | USD 3.24M | USD 142.43M |
| FY2023 | n/a | -USD 44.60M | -USD 36.10M | n/a | -10.31 | USD 13.72M | USD 15.91M | -USD 6.91M |
| FY2022 | USD 0 | -USD 42.35M | -USD 37.56M | n/a | -10.15 | USD 17.00M | USD 18.78M | USD 32.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 211.17M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 143.36M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 143.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 26.72M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 13.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 77.14M | n/a | n/a | n/a |
About Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Corbus Pharmaceuticals Holdings Inc's market cap?
Corbus Pharmaceuticals Holdings Inc's market capitalization is USD 211.17M.
What does Corbus Pharmaceuticals Holdings Inc do?
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.